
EIR Pharmaceuticals develops health and pharmaceutical products for humans and animals using a science-based approach. It applies biotechnology methods across drug discovery, development, and regulatory affairs to vet products for market readiness. The company combines scientific rigor with a business-focused philosophy to pursue commercially viable health benefits. Its team has experience in bringing products from concept through regulatory approval to commercialization. The approach targets both human and animal health markets.

EIR Pharmaceuticals develops health and pharmaceutical products for humans and animals using a science-based approach. It applies biotechnology methods across drug discovery, development, and regulatory affairs to vet products for market readiness. The company combines scientific rigor with a business-focused philosophy to pursue commercially viable health benefits. Its team has experience in bringing products from concept through regulatory approval to commercialization. The approach targets both human and animal health markets.
Stage & focus: Development-stage biotechnology company focused on human health, animal health, and consumer wellness
Platform: Proprietary biotechnology platform for applications across drug discovery, development, and regulatory vetting
Leadership: CEO / Board Manager: Dr. Andrew Skaff; Board Chair: Dr. Bill Duncan
Founded: 2018
Investor activity: Listed as an investor in at least one external financing round (investor in a Series A round disclosed in January 2024)
Health, wellness, and pharmaceutical product development across animal health, human consumer goods, and human health therapeutics.
2018
Biotechnology
“Has acted as an investor in at least one disclosed financing round (listed among investors in a Series A round in January 2024)”